Icosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV Vaccine
Published
Icosavax Inc ICVX announced topline interim results from its Phase 1 trial of IVX-A12 against the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. • IVX-A12 was generally well-tolerated across all dosage groups. • Solicited local and systemic adverse events (AEs)…
#icosavaxinc #phase1 #rsv #solicited #nabs #gmts #rsvbnabs #iuml #aphase2 #phase2